The U.S. Food and Drug Administration (FDA) has approved a new cell-based therapy designed to help restore the immune system and reduce the risk of…
Blood cancer
A European Medicines Agency (EMA) committee is recommending expanded approval for Jaypirca (pirtobrutinib), an oral therapy used to treat chronic lymphocytic leukemia (CLL), a type…
Nearly two-thirds of adults ages 80 and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), two related types of…
Adding iadademstat, an experimental blood cancer drug, to standard of care treatment for acute myeloid leukemia (AML) appeared to be safe and effective in…
The U.S. Food and Drug Administration (FDA) has approved a new formulation of the anticancer therapy nilotinib, branded Cavhanza, to treat certain people with chronic…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to STX-0712, an experimental therapy Solu Therapeutics is developing to treat chronic myelomonocytic…
The U.S. Food and Drug Administration (FDA) has approved a new combination therapy — Inqovi (decitabine and cedazuridine) plus Venclexta (venetoclax) — to treat adults…
A new genetic test for a group of blood cancers known as myeloid malignancies is expected to soon be available to certain people in…
The U.S. Food and Drug Administration (FDA) has named Terns Pharmaceuticals’ investigational oral agent TERN-701 a breakthrough therapy for potential use in certain people…
In adults newly diagnosed with a type of blood cancer called core-binding factor acute myeloid leukemia (CBF-AML), genetic mutations present before treatment do not…
